AVEO Oncology, EUSA Pharma announce updated interim results from phase II portion of the TiNivo study in renal cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AVEO Oncology and EUSA Pharma announced the presentation of updated interim results from the phase II portion of the TiNivo study, a phase Ib/II multicenter trial of oral tivozanib (Fotivda) in combination with intravenous nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of advanced or metastatic renal cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login